- What is Guangzhou Sino-Israel Biotech Investment Fund (GIBF)'s primary investment focus?
- GIBF focuses on drug development and delivery companies that are at clinical or approaching clinical stages of development and aspire to establish activities in China. Their investment range is typically $5-20 million per ticket.
- When was GIBF established and what is its current fund status?
- GIBF was established in 2016 and is currently investing out of its second fund, which has a size of $300 million. Their first fund, totaling $100 million, completed its investment period in 2021.
- Which stages of investment does GIBF typically target?
- GIBF targets Pre-Seed, Seed, and A Round investment stages.
- Can you name some of GIBF's portfolio companies?
- GIBF's portfolio includes companies such as Nectin Therapeutics, which raised $36 million in an A Round, and Kamari Pharma, which raised $31 million in an A Round.
- What is the geographic focus of GIBF's headquarters?
- GIBF's headquarters are located in Tel Aviv-Yafo, Israel.
- Who are some of the key individuals on GIBF's leadership team?
- The leadership team includes Dr. Yehoshua (Shuki) Gleitman as Chairman, Avner Lushi as CEO, and Prof. Shlomo Noy as Chief Medical Officer.
- What is GIBF's sector concentration?
- GIBF shows a strong concentration in the Health Tech & Life Sciences sector, with all six of its listed portfolio companies falling into this category.
- What was the size of GIBF's first fund?
- GIBF's first fund, established in March 2016, had an amount of $100 million.
- When did GIBF raise its second fund and what was its size?
- GIBF raised its second fund in May 2021, with an amount of $300 million.